Company Overview of OPKO Biologics
OPKO Biologics, a development stage biopharmaceutical company, is engaged in the development of proprietary versions of already-approved therapeutic proteins. Its technology, Carboxyl Terminal Peptide (CTP) is used to develop new and proprietary versions of existing therapeutic proteins that have longer life spans than therapeutic proteins without CTP. The company’s products under development include human growth hormone, which is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone; and factor IX that is offered to Hemophilia B patients to control blood clotting or coagulation. Its products under development als...
7 Golda Meir Street
Weizmann Science Park
Key Executives for OPKO Biologics
Chief Executive Officer and Director
President, Director and Member of Governance Committee
Chief Financial Officer and Principal Accounting Officer
Chief Operating Officer of Prolor Biotech Ltd
Director and Chief Scientific Officer of Prolor Biotech Ltd
Compensation as of Fiscal Year 2014.
OPKO Biologics Key Developments
PROLOR Biotech, Inc.(TASE:PBTH) dropped from TA-100 Index
Sep 2 13
PROLOR Biotech, Inc. will be removed from TA-100 Index.
PROLOR Biotech, Inc., Special/Extraordinary Shareholders Meeting, Aug 28, 2013
Jul 29 13
PROLOR Biotech, Inc., Special/Extraordinary Shareholders Meeting, Aug 28, 2013.
PROLOR Biotech, Inc. to Present Positive Results from Preclinical Studies of Long-Acting Clotting Factor VIIa-CTP at ISTH 2013
Jul 3 13
PROLOR Biotech, Inc. announced that the company will present new results from preclinical studies of its long-acting clotting factor VIIa (Factor VIIa-CTP), a next-generation investigational therapy in advanced preclinical development for the potential treatment of hemophilia. The data provide further evidence that Factor VIIa-CTP has the potential to be administered by subcutaneous (SC) injection as well as intravenously (IV), which would facilitate its prophylactic use by patients on an ongoing basis. The study results will be discussed in an oral presentation at the XXIV Congress of the International Society of Hemostasis and Thrombosis (ISTH). Currently available commercial factor VIIa must be administered through IV infusion, which can be onerous for patients. This limits its use for prophylactic treatment and can require frequent administrations if patients are treated only "on demand" when a bleeding episode occurs. The new preclinical results being presented at the ISTH Congress further confirm the efficacy of PROLOR's long-acting Factor VIIa-CTP and show that it has the potential to be administered using a simple SC injection. The combination of a long-acting product coupled with the ability to be administered by SC injection could change the way that factor VIIa is used, potentially allowing individuals with hemophilia to self-administer the drug at home on a prophylactic basis, improving their quality of life and potentially reducing the need for on-demand treatment of bleeding episodes.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries